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Introduction: We have previously identified endogenously citrullinated peptides derived from fibrinogen in
rheumatoid arthritis (RA) synovial tissues. In this study, we have investigated the auto-antigenicity of four of those
citrullinated peptides, and explored their feasibility to target anti-citrullinated protein/peptide antibodies (ACPA).
Methods: The autoantigenic potential of the fibrinogen peptides was investigated by screening 927 serum samples
from the Epidemiological Investigation of RA (EIRA) cohort on a peptide microarray based on the ImmunoCAP
ISAC® system. In order to assay for ACPA blocking, two independent pools of purified ACPA were incubated with
the respective targeting peptide prior to binding to cyclic citrullinated peptide (CCP)2 using the CCPlus® ELISA kit.
Results: Two peptides derived from the fibrinogen α chain, Arg573Cit (563-583) and Arg591Cit (580-600), referred to as
Cit573 and Cit591, and two peptides from the fibrinogen β chain, Arg72Cit (62-81) and Arg74Cit (62-81) (Cit72 and
Cit74), displayed 65 %, 15 %, 35 %, and 53 % of immune reactivity among CCP2-positive RA sera, respectively. In
CCP2-negative RA sera, a positive reactivity was detected in 5 % (Cit573), 6 % (Cit591), 8 % (Cit72), and 4 % (Cit74). In
the competition assay, Cit573 and Cit591 peptides reduced ACPA binding to CCP2 by a maximum of 84 % and 63 %
respectively. An additive effect was observed when these peptides were combined. In contrast, Cit74 and Cit72 were
less effective. Cyclization of the peptide structure containing Cit573 significantly increased the blocking efficiency.
Conclusions: Here we demonstrate extensive autoantibody reactivity against in vivo citrullinated fibrinogen epitopes,
and further show the potential use of these peptides for antagonizing ACPA.Introduction
Anti-citrullinated protein/peptide antibodies (ACPA) are a
hallmark of rheumatoid arthritis (RA) and are present in 60
to 70 % of RA patients [1, 2]. ACPA are commonly detected
by an enzyme-linked immunosorbent assay (ELISA), which
employs either one or a number of synthetic cyclic citrulli-
nated peptides (CCPs) [2]. ACPA are believed to emerge
following immune responses against citrulline containing
proteins, formed post-transcriptionally by deimination* Correspondence: per-johan.jakobsson@ki.se
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ginine deiminases (PADs). Fibrinogen [3], α-enolase [4],
vimentin [5], and collagen II [6] are well-characterized
citrullinated proteins targeted by ACPA.
ACPA have been suggested to play a role in the patho-
genesis of RA: the occurrence of these autoantibodies
antedates the clinical onset by several years [7], they are
associated with a more aggressive and destructive dis-
ease course (compared to the CCP-negative subset) [8],
and it has been suggested that antibodies targeting
citrullinated fibrinogen are involved in the development
of arthritis in mice [9]. The molecular mechanisms behind
the effects of ACPA have been addressed in severalpen Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Sequences of the fibrinogen α chain peptides 573 and
591 and β chain peptides 72 and 74
Peptide name Peptide sequence
Arg573 HHP GIA EFP SRG KSS SYS KQF
Cit573 HHP GIA EFP SXG KSS SYS KQF
Arg591 SKQ FTS STS YNR GDS TFE SKS
Cit591 SKQ FTS STS YNX GDS TFE SKS
Arg72, 74 APP PIS GGG YRA RPA KAA AT
Cit72 APP PIS GGG YXA RPA KAA AT
Cit74 APP PIS GGG YRA XPA KAA AT
R, Arginine; X, Citrulline
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nated fibrinogen were able to co-stimulate human and
murine macrophages via both Toll-like receptor 4 and FC
gamma receptor pathways [10, 11]. It was also shown that
anti-CCP antibodies could activate both the classical and
the alternative complement pathways in dose-dependent
manners in vitro [12]. In addition, the involvement of
ACPA in bone metabolism was identified, giving evidence
that anti-citrullinated vimentin antibodies cause osteoclas-
togenesis in vitro and in vivo in mice after intraperitoneal
transfer of purified antibodies [13]. In line with these re-
sults, and adding to the concept of ACPA pathogenicity,
ACPA levels were recently described to correlate with
the increased presence of neutrophil extracellular traps
(NETs) released during NETosis of both circulating and
synovial fluid RA neutrophils, and RA NETs could be a
source of citrullinated proteins [14].
Since ACPA are detected early in the time-course of the
disease and are likely involved in the pathophysiology, one
could speculate about the advantage of having a targeted
therapy against ACPA. Such treatment might be possible
by blocking ACPA with specific peptides, for example
using peptides derived from citrullinated fibrinogen. In
fact, a similar approach has been used for the blocking of
autoantibodies against the cardiac β1-adrenergic receptor.
A cyclic peptide (COR-1) that mimics the real epitope
structure was shown to prevent autoantibody-mediated
myocardial damage in an experimental model of immune
cardiomyopathy [15, 16].
Fibrinogen is one of the most extensively characterized
ACPA targets. We have previously identified endogen-
ously citrullinated residues at positions 573 and 591 within
the α fibrinogen chain, and at positions 72 and 74 in the β
chain from human arthritic synovial tissues, using mass
spectrometry (MS) [17]. Previously, several citrullinated
and non-citrullinated fibrin-derived peptides from the α
and β chains have been tested for recognition by ACPA
[18]. A total of 18 citrullinated peptides out of 71 tested
were found to contain epitopes recognized by RA CCP-
positive sera. Also, circulating immune complexes con-
taining citrullinated fibrinogen were shown to be present
in plasma from CCP-positive RA patients [19].
In the current study, we have analyzed sera from RA
patients for ACPA responses against peptides mimicking
the endogenously citrullinated epitopes, in the form of
citrullinated peptides generated in vitro, and also investi-
gated if these epitopes could be employed to target puri-
fied anti-CCP2 immunoglobulin G (IgG) molecules.
Methods
Patients
Serum from 927 RA patients (newly diagnosed patients
within 12 months of appearance of first symptoms; 402
CCP2 positive and 525 CCP2 negative) and 461 healthycontrols from the Epidemiological Investigation of RA
(EIRA) case-control cohort were collected. Control sam-
ples were randomly chosen from the Swedish population
registry, matching for age, sex, and residential area. All
serum and plasma samples were stored at −70 °C prior to
analysis. All patients fulfilled the American College of
Rheumatology-European League Against Rheumatism cri-
teria for RA [20]. CCP2-positive RA individuals used for
ACPA affinity purification were selected based on having
high anti-CCP2 antibody levels (>300 AU/ml, Immunoscan
CCPlus® assay, Euro-Diagnostica AB, Sweden). All patients
gave written informed consent. This study was approved
by the regional ethical committee at the Karolinska Institu-
tet (96-174), and performed in accordance with the Declar-
ation of Helsinki.
Peptide identification and synthesis
Endogenously citrullinated fibrinogen peptides of the α
chain, Arg573Cit (563-583) and the β chain, Arg72Cit
(62-81) and Arg74Cit (62-81), in synovial tissue from
RA patients were previously identified by MS [17]. α
chain peptide Arg591Cit (580-600) was also identified in
the study, but it was excluded from the results due to
the stringent criteria used (the peptide contains N and
Q). The occupancy rate for Cit591 was calculated to 0.8
%, using accurate mass-time tag and peak area for both
in vivo citrullinated peptide and its in vitro citrullinated
standard.
After optimization for solubility, length, and citrulline
position, citrullinated and unmodified peptides were ac-
quired with >95 % purity from ProImmune AB (Oxford,
United Kingdom) and used in a peptide microarray. The
corresponding N-terminally biotinylated peptides (ProIm-
mune AB, purity >95 %) were used in the competition as-
says. The sequences of these peptides are illustrated in
Table 1. Citrullinated or unmodified (that is, Arg contain-
ing) peptides Arg/Cit573, Arg/Cit72 and Arg/Cit74 were
dissolved in sterile distilled water, whereas Arg/Cit591
were dissolved in 10 % dimethyl sulfoxide (DMSO).
DMSO alone (10 %) did not show any reactivity in the
assay. In addition, Arg/Cit573 peptides were synthesized
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was incorporated in the N-terminal end. Similar results
were obtained when using either biotinylated or non-
biotinylated Arg/Cit573 peptides (data not shown).
Peptides derived from Cit573 (Table 2) were synthesized
in house by either manual or microwave-assisted standard
Fmoc-solid phase peptide synthesis (SPPS) on a 0.1 mM
scale using HBTU/DIPEA (Sigma-Aldrich, St. Louis, MO,
USA) as a coupling agent and piperidine (Sigma-Aldrich,
St. Louis, MO, USA) as an Fmoc deprotecting agent. The
two linear peptides (Cit573Lin1 and Cit573Lin2) were syn-
thesized (C-terminal acid) on a NovasynTGT resin (Merck
Millipore, Darmstadt, Germany) preloaded with Ser (0.2
mmol/g, Novabiochem, Merck Millipore, Darmstadt,
Germany). Cit573Lin1 was obtained in 93 % crude yield,
and MS analysis confirmed correct peptide identity: ob-
served mass 1,573.65 (M+H)+, calculated mass 1,573.68
(M+H)+. The yield of Cit573Lin2 was 89 % with an ob-
served mass of 1,153.43 (M+H)+ and calculated mass of
1,153.21 (M + H)+. Cit573 cyclic (Cit573Cyc) was syn-
thesized on a Tentagel Rink Amide resin (0.18 mmol/g,
Peptide International, KY, USA) using a C-terminal dia-
minobenzoic acid (Dbz) linker and an N-terminal cyst-
eine for cyclization by native chemical ligation [21, 22].
The peptide-Dbz was acylated and activated to form the
peptide N-benzylmidazolinone (Nbz) on the resin. Fol-
lowing the assembly of the peptide chain (peptide-Nbz),
in situ thioesterification and cyclization was carried out
in a pre-established cyclization/ligation buffer. Cit573-
Cyc was obtained in 46 % crude yield. MS analysis con-
firmed the peptide identify: experimental mass 2,433.93
((M+H)+ deconvoluted from the doubly and triply ions),
calculated mass 2,433.69 (M+H)+. Freeze-dried linear and
cyclic peptides were purified by reversed phase high per-
formance liquid chromatography (RP-HPLC; >95 % purity)
as determined by analytical HPLC (UV 215 nm) and MS.
Peptide microarray
Peptide microarray was performed as previously described
[23]. Briefly, peptides (sequences in Table 1) were immobi-
lized onto a chemically modified glass slide, sera from RA
patients and healthy controls were applied into the reac-
tions sites, and fluorescence intensity after incubation with
anti-human IgG antibody was acquired in a laser scanner
(LuxScan 10K, CapitalBio, Beijing, China). Final resultsTable 2 Sequences of cyclic and truncated peptides based on
the citrullinated fibrinogen α 573 peptide
Peptide name Peptide sequence
Cit573Cyc cyclo-CHHP GIA EFP SXG KSS SYS KQF
Cit573Lin1 GIA EFP SXG KSS SYS
Cit573Lin2 A EFP SXG KSS S
X, Citrulline; Cyc, cyclic; Lin1, Linear form 1; Lin2, Linear form 2for each citrullinated peptide were calculated by subtract-
ing the intensity values of the corresponding arginine-
containing control from the citrullinated peptide for all
RA patients and controls. Cutoff values were determined
as the 98th percentile of the healthy control responses.
Microarray data are available in the ArrayExpress database
under accession number [EMBL:E-MTAB-3606].
Preparation of human ACPA (anti-CCP2 IgG antibodies)
ACPA were affinity purified as recently described [24].
Two different ACPA pools were prepared for the competi-
tion assays: ACPA pool I, containing autoantibodies puri-
fied from 11 plasma or serum samples (plasma n = 4, sera
n = 7); and ACPA pool II, containing 39 plasma or serum
samples (plasma n = 38, serum n = 1). Before pooling, each
purified ACPA sample was individually tested by in house
ELISA for immunoreactivity to fibrinogen Cit573 and
citrullinated fibrinogen 36-52 [24]. Anti-CCP2 reactivity
was determined using the Immunoscan CCPlus® assay. All
pooled samples were CCP2 positive.
CCP2 ELISA and competition assays
ACPA pools I and II were used at a concentration of 1.2
μg/ml (8 nM IgG). The autoantibodies were incubated
with the fibrinogen and fibrinogen-derived peptides at
room temperature for one hour. The mole quantities of
peptides tested were: 0.016, 0.16, 1.6, 16, 22, 49, 60, 80,
120, 160, 216, and 320 nmol in an incubation volume of
225 μl. ACPA blocking by the fibrinogen peptides was
subsequently assessed by measuring the remaining anti-
CCP2 reactivity. Cit573 and Cit591 were equally com-
bined and co-tested for ACPA blocking. Arginine pep-
tides (573, 591, 72, and 74) were used as negative
controls in all assays.
To further explore the blocking potential of Cit573,
a retrieval assay was performed, that is, the ability of
the peptide to compete with already CCP2-bound
ACPA was tested. ACPA pool I was added to the
CCP2 plate and incubated for one hour at room
temperature, followed by the addition of the peptides
(citrulline and unmodified peptides) at mole quantities
ranging from 16 to 320 nmol. ACPA pools incubated
with no peptide were defined as positive control, giv-
ing the maximum values of anti-CCP2 reactivity. Ar-
bitrary units were calculated according to the
standard curve given by the ELISA kit. Each experi-
ment had one standard curve. Mean values were cal-
culated and results are expressed as a function of
percentage of inhibition of ACPA from the peptide
amount (nmol).
Statistical analysis
Results are presented as mean ± standard error (SEM)
of values (two to seven experiments per ACPA pool),
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paired comparisons using GraphPad Prism 6 software
(La Jolla, CA, USA). Median values were also calculated
in order to consider non-Gaussian distributions. As the
mean and median values were generally coincident, the
Mann-Whitney U test was not selected for statistical
analysis. P <0.05 was assumed to denote a significant dif-
ference. Relative IC50 values (IC50 definition according
to International Union of Pharmacology Committee on
Receptor Nomenclature and Drug Classification – ‘the
molar concentration of an antagonist that reduces the
response to an agonist by 50 %’ [25]) were also calcu-
lated using GraphPad Prism 6 software. Cutoffs for the
ISAC system chip data were calculated as the 98th per-
centile reactivity among the 461 EIRA controls investi-
gated in parallel to the 927 RA patients.
Results
Peptide microarray - immunogenicity of fibrinogen
peptides
Immune reactivity of RA (n = 927) and healthy control
(n = 461) sera against four citrullinated fibrinogen pep-
tides was investigated. When all analyses were aligned to
the same 98 % specificity level, the diagnostic sensitivity
among all 927 RA patients was 20.0 % for Cit72, 25.2 %
for Cit74, 31.5 % for Cit573, and 9.8 % for Cit591. When
the patients were dichotomized according to anti-CCP2
status, the corresponding figures were 35.1 % (Cit72),
52.5 % (Cit74), 65.4 % (Cit573), and 14.7 % (Cit591) for
the anti-CCP2-positive patients, (Fig. 1a) and 8.4 %
(Cit72), 4.4 % (Cit74), 5.5 % (Cit573), and 6.1 % (Cit591)











Fig. 1 a. Percentage of responses among tested patients. Immune reactivit
patients. Positive immune reactivity (%) (dark grey) against each individual
light gray represents negative immune response (%) against each individua
frequency (%) of patient sera reacting to one, two, three, or four citrullinateOnly a subgroup of the controls investigated with anti-
CCP2 with the ISAC chip had anti-CCP2 data. However,
in a more recent and larger evaluation of EIRA where
578 controls were investigated for anti-CCP2, nine of
these controls were found to be anti-CCP2 positive. The
corresponding diagnostic specificity for anti-CCP2 is
thus 98.4 %, closely resembling the chosen ISAC specifi-
city of 98 %. Figure 1b demonstrates the proportion of
all patient sera (both CCP2 positive and negative) that
were positive for up to four of these peptides. A total
of 47 % of the 927 patients tested showed positive
antibody response to at least one of the four citrulli-
nated fibrinogen peptides. When stratified, 22 %
showed reactivity against one of the four peptides, 14
% showed reactivity against two peptides, 10 %
showed reactivity against three peptides, and 2 %
showed antibody responses to all four citrullinated fi-
brinogen peptides (Fig. 1b). Cutoff values were ap-
plied as the 98th percentile of the healthy control
responses; 2 % of control population showed weak
positive response to each peptide tested.ACPA blocking - inhibition of reactivity in the anti-CCP2
ELISA
We next sought to investigate if fibrinogen-derived pep-
tides (citrullinated and unmodified versions) were able to
compete with CCP2 for binding of patient-derived ACPA.
Hence we performed an ‘ACPA competition’ experiment,
where purified human ACPA was pre-incubated with our
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y (%) against the respective peptide in sera from CCP2-positive
citrullinated fibrinogen peptide in sera from CCP2-positive patients;
l citrullinated peptide in CCP2-positive sera tested. b. Relative
d fibrinogen peptides
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Cit573 resulted in the highest degree of ACPA blocking,
achieving 84 % inhibition of reactivity, with an IC50 of 59
μM± 8 (n = 6; Fig. 2a, left panel). Fibrinogen linear peptide
Cit591 resulted in a similar dose-response curve as Cit573.
A maximum of 63 % ACPA blocking was recorded for
Cit591, and the IC50 calculated was 194 μM±3 (n = 2;
Fig. 2a, right panel).
When the two peptides Cit573 and Cit591 were
equally mixed and tested in the competition assay, a sig-
nificantly higher degree of ACPA blocking was achieved,
reaching 91 % inhibition (data not shown). Using ACPA
pool II, Cit573 resulted in a slightly weaker ACPA inhib-
ition in comparison to that observed with ACPA pool I
(Fig. 2b, left panel). Approximately 50 % of ACPA in the
anti-CCP2 plate were blocked (IC50 548 μM± 100, n =
4). On the other hand, ACPA pool II targeted by Cit591
showed a similar result to that observed with ACPA pool
I (Fig. 2b, right panel; IC50 412 μM± 146, n = 4). When
equally combined, Cit573 and Cit591 blocked up to 75
% of ACPA from pool II (data not shown).a
b
Fig. 2 Dose-response curves representing the percentage of ACPA targete
respective peptides at different concentrations for one hour at room temp
blocking with citrulline or arginine-containing fibrinogen peptides from the
blocking with citrulline or arginine-containing fibrinogen peptides from the
amount (nmol). Y-axes show ACPA inhibition levels (%). Circles represent m
represent SEM. *P <0.05, **P <0.001No major inhibition was observed for any of the two
ACPA pools, when using the unmodified peptide version
Arg573 in the same experimental conditions as the citrul-
linated fibrinogen peptides (Fig. 2a and b, left panels). On
the other hand, Arg591 displayed 30 % inhibition when in-
cubated with ACPA pool I (Fig. 2a, right panel), but no in-
hibition was detected when incubated with ACPA pool II
(Fig. 2b, right panel). In comparison, a maximum ACPA
inhibition of 35 % and 26 % was observed for the citrulli-
nated fibrinogen β chain peptides Cit72 and Cit74, re-
spectively, while no inhibition was registered with the
corresponding unmodified peptides (data not shown). Re-
trieval experiments were performed using the Cit573 pep-
tide in order to evaluate the capability of this peptide to
compete with CCP2 for already bound ACPA. Addition of
Cit573 reverted up to 80 % of ACPA binding to the CCP2
ELISA plate (data not shown). No relevant retrieval cap-
acity was observed for the arginine control peptide.
To determine whether cyclization of the peptides im-
proves ACPA targeting, a cyclic version of the full-
length Cit573 peptide was synthesized (Cit573Cyc) andd by fibrinogen α chain peptides. ACPA was incubated with the
erature, before proceeding with the anti-CCP2 ELISA. a. ACPA (pool I)
α chain, 573 (left panel) and 591 (right panel). b. ACPA (pool II)
α chain, 573 (left panel) and 591 (right panel). X-axes show peptide
eans of two to seven experiments per ACPA pool and error bars
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version of Cit573 reached 92 % of ACPA inhibition
(Fig. 3a), with an IC50 of 28 μM± 5 (n = 3) when incu-
bated with ACPA pool I. The full residue span within
Cit573 may not be necessary for optimal ACPA binding,
therefore two truncated linear peptides of 15 and 11 res-
idues (Cit573Lin1 and Cit573Lin2), originating from the
full-length Cit573, were tested and found to provide 75 %
(IC50 51 μM± 6, n = 3) and 69 % (IC50 123 μM± 18, n = 2)
ACPA inhibition, respectively (Fig. 3a).
The linear truncated peptides were also incubated with
ACPA pool II. Here, Cit573Lin1 accomplished 47 % in-
hibition, with an IC50 of 186 μM± 67 (n = 2), while
Cit573Lin2 achieved 40 % inhibition, with an IC50 of
105 μM± 34 (n = 2) (Fig. 3b). Interestingly, the cyclic form
of the Cit573 peptide performed similarly in ACPA pool I
(approximately 90 %) as in ACPA pool II (Fig. 3b).
Discussion
In the present study we demonstrated extensive autoanti-
body reactivity against citrullinated fibrinogen epitopes,
previously identified in vivo in RA synovial membranes
[17]. We also showed that citrullinated peptides, corre-
sponding to these in vivo modified epitopes, can be used
as targeting agents, blocking a significant portion of ACPA
binding to CCP2, forming the basis of a possible future
therapeutic approach for ACPA-positive RA.
In the current study we have analyzed the antibody re-
sponse towards four citrullinated fibrinogen peptides in
sera from 927 RA patients, and 47 % of the patients were
positive for antibodies against at least one of the peptides.
The majority of antibody-positive patients were identified
in the CCP2-positive subset, but interestingly, between 4
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Fig. 3 Dose-response curves representing the percentage of ACPA targete
concentrations of the respective peptide for one hour at room temperature b
the Cit573 peptide, with the Cit573 truncated or cyclic forms or with the unm
experiment as in (a) but using ACPA pool II. X-axes show peptide amount (nm
means of two to seven experiments per ACPA poolagainst the citrullinated fibrinogen peptides, supporting
previous findings that the CCP2 detection kit leaves out pa-
tients who produce antibodies against citrullinated proteins
[26, 27].
In addition to the results described here, the same citrul-
linated fibrinogen peptides were also tested in a pre-RA co-
hort [28]. In that study, it was shown that antibodies
against Cit573 and Cit74 were detected at low frequencies
before RA onset, but at significantly increased frequencies
after disease onset, suggesting an involvement in RA pro-
gression. Antibodies against Cit591 and Cit72, on the other
hand, were detected at the earliest time points, pointing to
a role in disease onset.
It has been suggested that ACPA mediate disease by
promoting osteoclastogenesis [13], activation of the com-
plement system [12], induction of TNF-α secretion [10,
11], and enhancement of NETosis [14]. In mice, ACPA
targeting fibrinogen has been shown to enhance develop-
ment of arthritis [9]. Since we know that fibrinogen is
citrullinated in vivo, and that the specific epitopes investi-
gated here are expressed in vivo [17], we hypothesize that
ACPA of these specificities will be involved in RA patho-
genesis. Hence, we suggest that these specific peptide se-
quences could be used in the development of novel drugs
that will target pathogenic ACPA [29].
Additionally, and taking into account the possible associ-
ation of certain citrullinated peptides (Cit591 and Cit72)
with the disease onset, an alternative therapy would be to
induce tolerance of Cit591- or Cit72-reactive CCP-positive
RA patients with a Cit591- or Cit72-derived compound.
The use of self-antigens (or closely-related structures) to in-
duce tolerizing effects on dendritic cells has, for instance,
been previously used in cancer. Farkas et al. demonstrated
that mucin 1 transgenic mice developed transientin 1
in 2
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d by fibrinogen 573-derived peptides. ACPA was incubated at different
efore proceeding with the anti-CCP2 ELISA. a. ACPA (pool I) blocking with
odified arginine-containing 573 peptide as control. b. Corresponding
ol). Y-axes show ACPA inhibition percentage levels (%). Circles represent
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munized with a mucin 1 peptide [30, 31]. In systemic lupus
erythematosus (SLE), antigen-induced tolerance has been
widely addressed. A nucleosomal histone epitope (H471-94)
was shown to delay lupus nephritis when administered (sub-
cutaneously) to lupus-prone mice [32, 33], and it was also
shown to suppress the disease in mice through nasal toler-
ance [34]. In addition, mice with experimental SLE were
shown to have improved when treated with a peptide with a
structure based on a complementary determining region 1
of a human anti-DNA autoantibody [35].
Competition with circulating autoantibodies has been
successfully described in an animal model of immune car-
diomyopathy. In this model, autoantibodies recognizing
the β1-adrenergic receptor mediate myocardial damage
[36]. The pathogenic autoantibodies were targeted using
cyclic peptide COR-1, which mimics the main epitope of
β1-adrenergic receptor, and this approach prevented myo-
cardial damage. The safe usage of COR-1 has since been
demonstrated in a phase I clinical trial [16]. Moreover, the
blocking capacity of aptamers (small nucleic acids) was
successfully evaluated in neonatal rat cardiomyocytes
treated in vitro with anti-β1-adrenergic receptor autoanti-
bodies [37]. Also in models of SLE, where autoantibodies
targeting double-stranded DNA have been reported to
cause glomerulonephritis [38], administration of soluble
peptides that bind double-stranded DNA have been shown
to protect against antibody-mediated experimental renal
injury [39]. One relevant fact to discuss is if peptides or
small molecules carrying an epitope may give rise to
harmful immune complexes. Considering the size of the
peptides (for example, approximately 2 kDa), an immune
reaction against those is unlikely. In support, Diamond
et al. in 2011 [40] showed that the administration of a
soluble peptide (peptide with a consensus sequence that
interacts with anti-dsDNA antibodies, and inhibits
DNA binding and cross-reacts with anti-N-methyl-D-
aspartate receptor antibodies) to mice previously injected
in the hippocampus with a monoclonal anti-dsDNA anti-
body (R4A), did not induce aggregation or formation of
immune complexes, and the combination was not toxic.
On the contrary, the soluble peptide prevented antibody-
mediated tissue damage by restricting the deposition of
the antibodies in the glomeruli.
In line with these ideas, we have explored the capacity
of peptides mimicking the endogenously citrullinated
fibrinogen epitopes to prevent purified human ACPA
from binding to CCP2. We have demonstrated the cap-
acity of citrullinated fibrinogen peptides (Cit573 and
Cit591) to target affinity purified human ACPA. When
combined, the peptides blocked up to 91 % of the anti-
bodies. Cyclization of the Cit573 peptide improved
ACPA blocking, suggesting a more stable epitope pres-
entation, and activity was retained in truncated versionsof Cit573, demonstrating the possibility of simplifying
syntheses and production of blocking peptides. In order
to target the majority of ACPA, a large excess of block-
ing peptide was required. However, a rather small frac-
tion of all ACPA sub-specificities [24] is likely to be
subject to blocking when using only one single specifi-
city, for example Cit573, at a low concentration.
B-cell depletion therapy (rituximab) has been shown
to be more efficient in CCP-positive RA patients, in
comparison to the CCP-negative subset [41–43]. The de-
pletion of ACPA-producing CD20+ B cells correlates
with improved disease activity, although re-population
of naïve B cells induces relapse [44]. Hence, it would be
an interesting approach to target the ACPA directly,
hampering their capacity to propagate inflammation and
induce tissue damage. We argue that blocking of ACPA
with molecules based on the structures of citrullinated
fibrinogen peptides might be used for such a purpose,
and our data provides proof of the principle that block-
ing of ACPA may be developed into a new means of
treating RA.
Conclusions
We demonstrate that in vivo citrullinated fibrinogen epi-
topes found in RA synovial tissue are auto-antigenic.
These peptides can be used as additional biomarkers for
studies of ACPA sub-specificity profiles, as recently re-
ported [28]. We also demonstrate that these citrullinated
peptides can be used as probes for development of
ACPA-blocking compounds preventing, for instance, the
osteoclastogenesis and bone loss induced by ACPA or
other ACPA-pathogenic effects [13].
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